IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

June 30, 2008

Conditions
Neoplasms, Squamous Cell
Interventions
DRUG

gefitinib (Iressa)

250 mg oral tablet

DRUG

cisplatin

intravenous infusion

RADIATION

radiotherapy

radiation therapy

DRUG

Gefitinib (Iressa)

500 mg oral tablet

Trial Locations (25)

Unknown

Research Site, Aurora

Research Site, Dallas

Research Site, Brussels

Research Site, Ghent

Research Site, Leuven

Research Site, Hradec Králové

Research Site, Pardubice

Research Site, Pilsen

Research Site, Berlin

Research Site, Essen

Research Site, Münster

Research Site, Saarbrücken

Research Site, Bangalore

Research Site, Mumbai

Research Site, New Delhi

Research Site, Thiruvananthapuram

Research Site, Gliwice

Research Site, Krakow

Research Site, Lodz

Research Site, Lublin

Research Site, Warsaw

Research Site, Belgrade

Research Site, Kamenitz

Research Site, Taipei

Research Site, Taoynan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY